<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02683317</url>
  </required_header>
  <id_info>
    <org_study_id>R-2015-785-051</org_study_id>
    <nct_id>NCT02683317</nct_id>
  </id_info>
  <brief_title>Enteral Administration of Docosahexaenoic Acid to Prevent Retinopathy of Prematurity</brief_title>
  <official_title>Effect of Enteral Administration of Docosahexaenoic Acid on Development of the Retinopathy of Prematurity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether docosahexaenoic acid given by enteral
      feeding prevent retinopathy of prematurity and/or diminish its severity in preterm infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm neonates who start receiving enteral feeding will receive the intervention with
      docosahexaenoic acid (DHA) since the first day and throughout 14 days, one dose per day.

      The opthalmic evaluation will be done after 4-5 weeks after birth and followed until 42-45
      corrected gestational age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Regarding the Study phase, the intervention was a nutraceutical, docosahexaenoic acid, derived from omega 3 fatty acid family.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of retinopathy of prematurity (ROP)</measure>
    <time_frame>ROP will be evaluated from 4 to 5 weeks after birth throughout 42-45 of corrected gestational age.</time_frame>
    <description>The medical screening to determine the presence ROP will include the exhaustive search of injury on the zone, stage and the presence of plus disease in retina of the preterm infants. The measure unit is frequency of ROP (presence =1 or absence=0) registering the corrected gestational age of the first identification.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of ROP</measure>
    <time_frame>ROP will be evaluated as changes in each retina's eye from 4 to 5 weeks after birth throughout 42-45 of corrected gestational age</time_frame>
    <description>The study will determine the severity of retinopathy of prematurity as ordinal variable with frequencies, according to the following classification:
ROP stage 1 or threshold needs treatment:
ROP in Zone I any stage if it is associate to presence of Plus.
ROP stage 1 in Zone I + Plus disease
ROP stage 2 in Zone I + Plus disease
ROP stage 3 in Zone I + Plus disease
ROP in Zone I Stage 3 with or without Plus disease.
ROP in Zone II Stage 2 or 3 + Plus disease.
ROP Stage 2 or pre-threshold, require close monitoring:
ROP in Zone I, Stage 1 or 2 without Plus
ROP in Zone II, Stage 3 without Plus
ROP in zone II or III, Stage 1 or 2 without Plus, require periodic monitoring.
ROP in remission
Without retinopathy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Retinopathy of Prematurity</condition>
  <arm_group>
    <arm_group_label>DHA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group will receive 75 mg of docosahexaenoic acid per kilo of baseline weight in one dose per day, administered by enteral feeding throughout 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Control group will receive sunflower oil, the excipient of the DHA in our intervention.
They will receive it once a day, administered by enteral feeding throughout 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>docosahexaenoic acid</intervention_name>
    <description>Docosahexaenoic acid is a dietary supplement derived from algae.</description>
    <arm_group_label>DHA group</arm_group_label>
    <other_name>n-3 long chain polyunsaturated fatty acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>sunflower oil</intervention_name>
    <description>Sunflower similar to the excipient used in experimental group</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Birth weight &lt; 1500 g

          -  Plan to feed by enteral way at a short term

          -  Written informed consent, signed by both parents.

        Exclusion Criteria:

          -  Congenital malformations that avoid enteral feeding

          -  immunosuppressor diseases

          -  Need for major surgery

          -  Persistent bleeding at any level

          -  Mother taking n-3 supplements and planning to breastfed

          -  Parents who decline the authorization for participating in the study

          -  Early discharge to other hospital outside the metropolitan area
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariela Bernabe-Garcia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unit of Research in Nutrition, Pediatric Hospital, Instituto Mexicano del Seguro Social</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>López-Alarcón M, Bernabe-García M, Del Prado M, Rivera D, Ruiz G, Maldonado J, Villegas R. Docosahexaenoic acid administered in the acute phase protects the nutritional status of septic neonates. Nutrition. 2006 Jul-Aug;22(7-8):731-7. Epub 2006 Jun 5.</citation>
    <PMID>16750345</PMID>
  </reference>
  <reference>
    <citation>López-Alarcón M, Bernabe-García M, del Valle O, González-Moreno G, Martínez-Basilea A, Villegas R. Oral administration of docosahexaenoic acid attenuates interleukin-1β response and clinical course of septic neonates. Nutrition. 2012 Apr;28(4):384-90. doi: 10.1016/j.nut.2011.07.016. Epub 2011 Nov 12.</citation>
    <PMID>22079797</PMID>
  </reference>
  <reference>
    <citation>Bernabe-Garcia M, Lopez-Alarcon M, Villegas-Silva R, Mancilla-Ramirez J, Rodriguez-Cruz M, Maldonado-Hernandez J, Chavez-Rueda KA, Blanco-Favela F, Espinoza-Garcia L, Lagunes-Salazar S. Beneficial Effects of Enteral Docosahexaenoic Acid on the Markers of Inflammation and Clinical Outcomes of Neonates Undergoing Cardiovascular Surgery: An Intervention Study. Ann Nutr Metab. 2016;69(1):15-23. doi: 10.1159/000447498. Epub 2016 Jul 9.</citation>
    <PMID>27394149</PMID>
  </reference>
  <reference>
    <citation>Bernabe-Garcia M, López-Alarcon M, Salgado-Sosa A, Villegas-Silva R, Maldonado-Hernandez J, Rodríguez-Cruz M, Rivas-Ruiz R, Chavez-Sanchez L, Blanco-Favela FA, Mancilla-Ramirez J, Gordillo-Alvarez V, Madrigal-Muñiz O. Enteral Docosahexaenoic Acid Reduces Analgesic Administration in Neonates Undergoing Cardiovascular Surgery. Ann Nutr Metab. 2016;69(2):150-160. Epub 2016 Nov 2.</citation>
    <PMID>27806350</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Mariela Bernabe García</investigator_full_name>
    <investigator_title>Full Time Researcher</investigator_title>
  </responsible_party>
  <keyword>DHA</keyword>
  <keyword>Retinopathy of Prematurity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

